Business
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates
Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based program under AbbVie agreement Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2 Appoints Sara Bonstein as chair of board of directors WALTHAM, Mass., Jan. 08,
About this update from Xilio Therapeutics, Inc.
[{"type":"text","content":"Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027","length":234,"tagName":"p"},{"type":"text","content":"Achieved development milestone for masked antibody-based program under AbbVie agreement","length":87,"tagName":"p"},{"type":"text","content":"Nominated development candidate for wholly-owned masked T cell engager program targeting CLDN18.2","length":97,"tagName":"p"},{"type":"text","content":"Appoints Sara Bonstein as chair of board of directors","length":53,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today highlighted upcoming milestones and recent corporate updates.","length":287,"tagName":"p"},{"type":"text","content":"“2025 was marked by robust execution at Xilio as we delivered on key priorities across our deep portfolio of differentiated I-O therapies, demonstrated additional clinical validation of our masking technology and further strengthened our financial position through strategic partnerships and our recent equity financing,” said René Russo, Pharm.D., president and chief executive officer of Xilio. “In the year ahead, we have a strong foundation to advance our potential best-in-class bispecific PD-1/IL-2 and T cell engager programs toward the clinic and maximize the value of our vilastobart and efarindodekin alfa programs through strategic partnerships.”","length":657,"tagName":"p"},{"type":"text","content":"Xilio also announced the appointment of Sara Bonstein as chair of the board of directors, following the retirement of Paul Clancy. Dr. Russo continued, “Sara has been an invaluable member of our board since 2021 and brings more than two decades of executive leadership in finance, corporate strategy and business operations in the biotechnology industry, as well as extensive experience advancing novel therapies from discovery through commercialization. I look forward to continuing to partner with Sara as we advance our pipeline of masked immuno-oncology therapies through development. On behalf of the entire board, I’...